Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-533-8 | CAS number: 4904-61-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral
2000: According to OECD 422; GLP; 10 Sprague Dawley rats; 30, 100, 300 mg/kg bw/day; no specific target organ toxicity; no mortality; NOAEL males and females: 100 and 30 mg/kg bw/day, resp. (K1)
Inhalation
1999: No guideline stated; GLP not specified; 10 Sprague Dawley rats; 5, 50, 260 ppm; no specific target organ toxicity; no mortality; NOAEC 33.4 mg/m³ (K2)
Dermal
No study available
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- 1986
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD (SD)IGS BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ORGANISMS
- Age: males 59 days, females 52 days (approximately)
- Number of animals: 10 per sex and per dose group
- Further information: see references - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- ADMINISTRATION / EXPOSURE
- Vehicle: corn oil
- Concentration in vehicle: 6, 20, 60 mg/ml
- Total volume applied: 5 ml/kg bw/dose - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysis of the test substance indicated that the test substance was homogeneously distributed at all levels and that the concentrations were at the
targed level. Stability results indicated that the test substance was stable at all concentrations. - Duration of treatment / exposure:
- males through test day 55; females 4 weeks premating through 4-day lactation period
- Frequency of treatment:
- daily
- Dose / conc.:
- 30 other: mg/kg bw/day
- Dose / conc.:
- 100 other: mg/kg bw/day
- Dose / conc.:
- 300 other: mg/kg bw/day
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Post-exposure period: none
MATING PROCEDURES: mating period approximately 1-2 weeks - Observations and examinations performed and frequency:
- PARAMETERS ASSESSED DURING STUDY P:
- Clinical signs: at least once daily
- Mortality: at least twice daily
- Body weight: weekly, for females also on lactation days 0 and 4
- Food consumption: weekly
- Ophthalmoscopic examination: Both eyes of all rats prior to study and on test day 24, prior to clinical pathology evaluation (surviving rats).
- Clinical pathology evaluation on all rats after 4 weeks of dosing, and on male rats at the time of scheduled sacrifice:
- hematology / coagulation: erythrocyte count, total leukocyte count, platelet count, hemoglobin concentration, hematocrit, differential
leukocyte count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, absolute reticulocyte counts, red cell distribution width, microscopic blood examination, activated partial thromoboplastin time, prothrombin time.
- clinical chemistry: alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, sorbitol dehydrogenase, glucose, urea nitrogen, calcium, inorganic phosphorus, total bilirubin, cholesterol, triglyceride, creatinine, total protein, albumin, globulin, sodium, potassium, chloride.- urine: volume, specific gravity, urobilinogen, blood, glucose, protein, appearance (quality, transparency, color), pH, bilirubin, ketones, sediment microscopy.
- Other: Neurobehavioral Functional Observational Battery (FOB) on all study rats prior to exposure and following approximately 4 weeks of test
substance administration.
OFFSPRING: gestation length, mating index, gestation index, fecundity index, implantation site numbers, implantation efficiency, sex ratio, pups
born alive, viability index - Sacrifice and pathology:
- ORGANS EXAMINED AT NECROPSY (MACROSCOPIC AND MICROSCOPIC):
- Time: Sacrifice and necropsy of males on day 56 and of females on days 56-64.
- Organ weights P: liver, kidneys, adrenal glands, thymus, brain, spleen, heart, testes, epididymides. Calculation of ratios to final body and brain
weights.
- Histopathology P:
all high dose and control rats: testes, epididymides, ovaries, gross lesions;
5 high dose and 5 control rats per sex: additional 37 tissues 5 females from other groups with >= 1 offspring: liver - Other examinations:
- no other examinations
- Statistics:
- STATISTICAL METHODS:
- All weight parameters (P, not F), gestation length, clinical pathology, grip strength, foot splay: One-way analysis of variance followed with
Dunnett's test or Kruskal-Wallis test; followed with Dunn's test.
- Incidence of clinical and FOB observations; mating, gestation, fecundity indexes: Sequential application of Cochran-Armitage test for trend
- Implantation site number and efficiency, sex ratio, pups born alive, viability index: Jonckheere's test - Mean pup weights: Linear contrast of the least square means
- Motor activity: Levene's and Shapiro-Wilk tests followed by repeated measures analysis of variance followed by contrasts of Jonckheere's trend test - Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no test substance-related effects on clinical observations
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One high-dose male was sacrificed in extremis due to a dosing-related injury.
One high-dose female was found dead on day 57 from dystocia.
No other deaths occured during the study. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Decreased body weight gain was observed and considered to be compound-related and of biological significance:
300 mg/kg males (-19 % for days 1-56, not statistically significant; weight -7%);
100 and 300 mg/kg females (only during gestation: gains -13% and -20%, weights -7% and -12%, respectively, statistically significant). - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Increased food consumption was observed and considered to be compound-related and of biological significance:
300 mg/kg males (+19%)
100 mg/kg (+7%, not statistically significant) and 300 mg/kg females (+13%, statistically significant) during gestation. - Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- 300 mg/kg males (-33%)
100 and 300 mg/kg females during gestation (+14 and +29%, respectively, statistically significant). - Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No test substance-related effects
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- No test substance-related effects in neurobehavioral parameters and motor activity
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Liver weights were statistically significantly increased in several dosed groups:
Males: 30 mg/kg +10% relative; 100 mg/kg +14 % absolute, +21% relative; 300 mg/kg +34 % absolute, +45% relative.
Females: 100 mg/kg +15% relative; 300 mg/kg +36% absolute, +42% relative.
In females it was associated with microscopic centrilobular hepatocellular hypertrophy, which is indicative of a physiological response-induction of enzymes associated with metabolism, and is not considered biologically adverse.
In males, minimal diffuse hypertrophy may have occurred, which is hard to identify histologically.
- Kidney weights were statistically significantly increased in several dosed groups:
Males: 100 mg/kg +16% absolute, +21% relative; 300 mg/kg +22%, +37% relative
Females: 100 mg/kg +11% relative; 300 mg/kg +15% absolute, +17% relative
These findings were associated with some evidence of diuresis in high-dose males and females, but there were no compound-related changes in any other kidney parameter including histopathology. These weight changes may be an adaptive response to the physiological changes that occur following administration of large doses of a test material. They were not considered to be biologically adverse. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No test substance-related effects
- Histopathological findings: non-neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Description (incidence and severity):
- - Fertility index: no test substance-related effects
- Duration of gestation: no test substance-related effects
- Gestation index: no test substance-related effects
- Number of implantations: no test substance-related effects
- Mating index: no test substance-related effects
- Implantation efficiency: no test substance-related effects
- Pups born alive: no test substance-related effects - Details on results:
- TOXIC RESPONSE/EFFECTS BY DOSE LEVEL:
- Body weights of pups in the 300 mg/kg group were significantly decreased (-17% on lactation day 4).
- Sex and sex ratios: no test substance-related effects
- Viability index: no test substance-related effects - Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- Remarks on result:
- other: associated with increased FC and decreased food efficiency
- Dose descriptor:
- NOAEL
- Effect level:
- 30 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- body weight and weight gain
- Critical effects observed:
- no
- Conclusions:
- According to the outcome of the study it is concluded that the no-observed -adverse-effect level (NOAEL) was 100 mg/kg for male rats and 30 mg/kg/day for female rats.
- Executive summary:
Male and female rats were administered an oral, daily dose of 0, 30, 100 or 300 mg/kg/day 1,5,9 -cyclododecatriene.
According to the outcome of the study it is concluded that the no-observed -adverse-effect level (NOAEL) was 100 mg/kg for male rats and 30 mg/kg/day for female rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 30 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Principles of method if other than guideline:
- Method: as described in the reference (Bamberger et al)
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD(R)(SD)BR
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Strain: Crl:CD(R)(SD)BR
- Source: Charles River Breeding Laboratories, Raleigh (USA)
- Age: ca. 8 weeks
- Weight at study initiation: ca. 245 g (mean)
further information : see reference (Bamberger et al) - Route of administration:
- inhalation
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Remarks on MMAD:
- MMAD / GSD: Particle size: vapour at 5 and 50 ppm;
aerosol at 260 ppm; particle size: MMAD 3.5 or 3.7 um, 35 or 36% of particles < 3 um; 98 or 99% of particles < 10 um - Details on inhalation exposure:
- see reference
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- -analysed by gas chromatography and gravimetric analysis in 60 min intervalls
- Duration of treatment / exposure:
- 2 weeks
- Frequency of treatment:
- 6 hours/day, 5 days/week, total 9 exposures
- Dose / conc.:
- 5 ppm
- Remarks:
- 33.4 mg/m3; 5 +/- 0 ppm (analytical concentration)
- Dose / conc.:
- 50 ppm
- Remarks:
- 334 mg/m3; 51 +/- 1.0 ppm (analytical concentration)
- Dose / conc.:
- 260 ppm
- Remarks:
- 1740 mg/m3; 260 +/- 5.7 ppm (analytical concentration)
- No. of animals per sex per dose:
- 10 per group
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Number of animals: 10 animals per group
- 2 groups per concentration:
1 for standard toxicological evaluations
1 for neurotoxicity testing
-Post-exposure period: 2 weeks (half of the animals)
- SATELLITE GROUPS AND REASONS THEY WERE ADDED: neurotoxicity - Observations and examinations performed and frequency:
- - Clinical signs: groupwise during exposure, individually after each exposure
- Mortality: before / during / after exposure
- Body weight: before each exposure; daily except weekends during recovery period
- Haematology: end of exposure period
- Biochemistry: end of exposure period
- Urinalysis: end of exposure period - Sacrifice and pathology:
- ORGANS EXAMINED AT NECROPSY (MACROSCOPIC AND MICROSCOPIC):
-5 animals per group sacrificed 1 day after last exposure; other animals sacrificed after (additional) 14 days of recovery
- Macroscopic: weights of liver, kidneys, lungs, testes, brain; examination of liver, kidneys, lungs, duodenum, heart, spleen, brain (cerebrum, midbrain, cerebellum, medulla / pons), spinal cord, stomach, jejunum, ileum, pancreas, cecum, colon, rectum, mesenteric lymph node, thymus, adrenal glands, sciatic nerve, thyroid gland, parathyroid glands, trachea, esophagus, pharynx / larynx, eyes, prostate, seminal vesicles, urinary bladder, testes epididymides, sternum (with bone marrow), nose; samples of all plus of gross lesions were saved
- Microscopic: control and high dose animals sacrificed without recovery period: all organs listed above (macroscopic examination); animals from other dose groups sacrificed without recovery and control and high dose animals sacrificed after recovery: nose, pharynx / larynx, lungs, liver, kidneys - Other examinations:
- OTHER EXAMINATIONS:
Neurotoxicity groups Functional observational battery (FOB) of tests + motor activity (MA) evaluations immediately after 4th and 9th exposures; Neuropathology evaluation in 6/10 control and high dose animals after 9th exposure - Statistics:
- - Mean, standard deviation, standard error;
- Incidences: Cochran-Armitage test for trend;
- Body & organ weights: one-way analysis of variance;
- Pairwise comparison with controls: Dunnett's test
- Homogeneity of variances: Bartlett's test
- Clinical pathology: one-way analysis of variance, Bartlett's test; Dunnett's test for comparison of means to control; Kruskal-Wallis test and Mann-Whitney U test when Bartlett's test showed significance (p<0.005)
- FOB: Cochran-Armitage test for trend, Fisher's exact test for significance of deviations from control
- Other test in neurobehavioral evaluations: Bartlett's test for homogeneity (p<0.005), univariate analysis of variance, Shapiro-Wilk's test, Levene's test, Kruskal-Wallis followed by Dunn's test, block (all p<0.05) - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Irregular respiration in the high dose group. Other clinical observations occurred sporadically in all groups including controls and were considered incidental.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- significantly reduced at >= 50 ppm, reversible
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Compound-related or biologically adverse changes did not occur during this study.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Compound-related or biologically adverse changes did not occur during this study.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Statistically significant or biologically adverse changes did not occur during this study.
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- A diminished or absent response to an alerting stimulus was observed in the high dose group. Mean foot splay was significantly decreased on days 4 and 9 in the high dose group. The incidence of defecation was decreased in the 50 and 260 ppm groups during the motor activity assessments. Beyond this, there were no statistically significant or toxicologically remarkable neurobehavioral differences between the control and treatment groups.
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related changes were observed. (Absolute but not relative lung weights were reduced in the high dose group.)
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related changes were observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Effects only occurred in the nasal tissue of the high dose group. Minimal degeneration / necrosis of olfactory epithelium occurred in the anterior portion of the nose of 4/5 rats exposed to 260 ppm. This lesion was observed neither in the 260 ppm recovery group, which suggests reversibility, nor in the lower dosed groups.
- Dose descriptor:
- NOAEC
- Effect level:
- 33.4 mg/m³ air
- Sex:
- male
- Basis for effect level:
- other: no adverse effects observed
- Dose descriptor:
- LOAEC
- Effect level:
- 334 mg/m³ air
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- Critical effects observed:
- no
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 33.4 mg/m³
- Study duration:
- subacute
- Experimental exposure time per week (hours/week):
- 30
- Species:
- rat
Repeated dose toxicity: inhalation - local effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Principles of method if other than guideline:
- Method: as described in the reference (Bamberger et al)
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD(R)(SD)BR
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Strain: Crl:CD(R)(SD)BR
- Source: Charles River Breeding Laboratories, Raleigh (USA)
- Age: ca. 8 weeks
- Weight at study initiation: ca. 245 g (mean)
further information : see reference (Bamberger et al) - Route of administration:
- inhalation
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Remarks on MMAD:
- MMAD / GSD: Particle size: vapour at 5 and 50 ppm;
aerosol at 260 ppm; particle size: MMAD 3.5 or 3.7 um, 35 or 36% of particles < 3 um; 98 or 99% of particles < 10 um - Details on inhalation exposure:
- see reference
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- -analysed by gas chromatography and gravimetric analysis in 60 min intervalls
- Duration of treatment / exposure:
- 2 weeks
- Frequency of treatment:
- 6 hours/day, 5 days/week, total 9 exposures
- Dose / conc.:
- 5 ppm
- Remarks:
- 33.4 mg/m3; 5 +/- 0 ppm (analytical concentration)
- Dose / conc.:
- 50 ppm
- Remarks:
- 334 mg/m3; 51 +/- 1.0 ppm (analytical concentration)
- Dose / conc.:
- 260 ppm
- Remarks:
- 1740 mg/m3; 260 +/- 5.7 ppm (analytical concentration)
- No. of animals per sex per dose:
- 10 per group
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Number of animals: 10 animals per group
- 2 groups per concentration:
1 for standard toxicological evaluations
1 for neurotoxicity testing
-Post-exposure period: 2 weeks (half of the animals)
- SATELLITE GROUPS AND REASONS THEY WERE ADDED: neurotoxicity - Observations and examinations performed and frequency:
- - Clinical signs: groupwise during exposure, individually after each exposure
- Mortality: before / during / after exposure
- Body weight: before each exposure; daily except weekends during recovery period
- Haematology: end of exposure period
- Biochemistry: end of exposure period
- Urinalysis: end of exposure period - Sacrifice and pathology:
- ORGANS EXAMINED AT NECROPSY (MACROSCOPIC AND MICROSCOPIC):
-5 animals per group sacrificed 1 day after last exposure; other animals sacrificed after (additional) 14 days of recovery
- Macroscopic: weights of liver, kidneys, lungs, testes, brain; examination of liver, kidneys, lungs, duodenum, heart, spleen, brain (cerebrum, midbrain, cerebellum, medulla / pons), spinal cord, stomach, jejunum, ileum, pancreas, cecum, colon, rectum, mesenteric lymph node, thymus, adrenal glands, sciatic nerve, thyroid gland, parathyroid glands, trachea, esophagus, pharynx / larynx, eyes, prostate, seminal vesicles, urinary bladder, testes epididymides, sternum (with bone marrow), nose; samples of all plus of gross lesions were saved
- Microscopic: control and high dose animals sacrificed without recovery period: all organs listed above (macroscopic examination); animals from other dose groups sacrificed without recovery and control and high dose animals sacrificed after recovery: nose, pharynx / larynx, lungs, liver, kidneys - Other examinations:
- OTHER EXAMINATIONS:
Neurotoxicity groups Functional observational battery (FOB) of tests + motor activity (MA) evaluations immediately after 4th and 9th exposures; Neuropathology evaluation in 6/10 control and high dose animals after 9th exposure - Statistics:
- - Mean, standard deviation, standard error;
- Incidences: Cochran-Armitage test for trend;
- Body & organ weights: one-way analysis of variance;
- Pairwise comparison with controls: Dunnett's test
- Homogeneity of variances: Bartlett's test
- Clinical pathology: one-way analysis of variance, Bartlett's test; Dunnett's test for comparison of means to control; Kruskal-Wallis test and Mann-Whitney U test when Bartlett's test showed significance (p<0.005)
- FOB: Cochran-Armitage test for trend, Fisher's exact test for significance of deviations from control
- Other test in neurobehavioral evaluations: Bartlett's test for homogeneity (p<0.005), univariate analysis of variance, Shapiro-Wilk's test, Levene's test, Kruskal-Wallis followed by Dunn's test, block (all p<0.05) - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Irregular respiration in the high dose group. Other clinical observations occurred sporadically in all groups including controls and were considered incidental.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- significantly reduced at >= 50 ppm, reversible
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Compound-related or biologically adverse changes did not occur during this study.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Compound-related or biologically adverse changes did not occur during this study.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Statistically significant or biologically adverse changes did not occur during this study.
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- A diminished or absent response to an alerting stimulus was observed in the high dose group. Mean foot splay was significantly decreased on days 4 and 9 in the high dose group. The incidence of defecation was decreased in the 50 and 260 ppm groups during the motor activity assessments. Beyond this, there were no statistically significant or toxicologically remarkable neurobehavioral differences between the control and treatment groups.
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related changes were observed. (Absolute but not relative lung weights were reduced in the high dose group.)
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related changes were observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Effects only occurred in the nasal tissue of the high dose group. Minimal degeneration / necrosis of olfactory epithelium occurred in the anterior portion of the nose of 4/5 rats exposed to 260 ppm. This lesion was observed neither in the 260 ppm recovery group, which suggests reversibility, nor in the lower dosed groups.
- Dose descriptor:
- NOAEC
- Effect level:
- 33.4 mg/m³ air
- Sex:
- male
- Basis for effect level:
- other: no adverse effects observed
- Dose descriptor:
- LOAEC
- Effect level:
- 334 mg/m³ air
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- Critical effects observed:
- no
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 334 mg/m³
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Oral
A combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (no limit test) was performed according to OECD 422 and in compliance with GLP. Ten Sprague Dawley rats per sex per dose were treated daily orally by gavage with 30, 100, or 300 mg/kg bw/day of the test substance equivalent to 6, 20, and 60 mg/ml concentration in vehicle, respectively. The vehicle used was corn oil. The total volume applied was 5 ml/kg bw/dose. Males and females were exposed through test day 55 and from four weeks pre-mating through 4-day lactation period, respectively. Control animals were included and received concurrent vehicle treatment. No clinical signs were reported. One high-dose male was sacrificed in extremis due to a dosing-related injury. One high-dose female was found dead on day 57 from dystocia. No other deaths occurred during the study and the observed deaths were not considered to be treatment related. Decreased body weight gain was observed and considered to be compound-related and of biological significance. At 300 mg/kg bw/day, males experienced a decrease in body weight of -19 % for days 1-56 which was not statistically significant; weight -7%. At 100 and 300 mg/kg bw/day, females experienced a decrease only during gestation: gains -13% and -20%, weights -7% and -12%, respectively, statistically significant). Increased food consumption was observed and considered to be compound-related and of biological significance. At 300 mg/kg bw/day, males had increased food intake (+19%). At 100 and 300 mg/kg bw/day, females had increased food intake (+7%, not statistically significant and +13%, statistically significant, respectively) during gestation. Accordingly, food efficiency was also affected by treatment; at 300 mg/kg bw/day, males had decreased efficiency (-33%) and at 100 and 300 mg/kg bw/day, females during gestation had increased efficiency (+14 and +29%, respectively, statistically significant). Thus, the NOAEL for males and females was concluded to be 100 mg/kg bw/day and 30 mg/kg bw/day, respectively (2000, K1).
In addition, a combined repeated dose/reproductive developmental toxicity study in Sprague Dawley rats treated orally with test substance was only available in the original study language (Japanese) and an IUCLID dossier entry available on the NIHS Japan was used (2007, K4). Results obtained in this study are similar to those retrieved by Malley et al. (2002). However, effects on the liver were here regarded as adverse. It has to be noted that no historical ranges of the control were given and results were not properly discussed in the IUCLID dossier entry. Thus, it may be assumed that effects on the liver were adaptive and a non-adverse reaction as has been concluded for effects on the liver by Malley et al. (2002).
Inhalation
Two studies investigating the repeated exposure toxicity potential of the test substance are available.
A repeated dose toxicity (no limit test) was performed (no guideline reported) pre-GLP. Twenty male Sprague Dawley rats per dose were treated whole body by inhalation with 1.64 mg/l of the test substance. No post exposure period was included. Animals were exposed for 6 hours/day for ten days daily. No control animals were included. Peripheral vasodilation was noted throughout the study. A slight twitching only at the beginning of each exposure period through days 3 to 10 was observed. A lack of activity was observed throughout each exposure period. A LOAEC of 1.64 mg/l was concluded (1965, K2).
A repeated dose toxicity (no limit test) was performed (no guideline reported, GLP not specified). Ten male Sprague Dawley rats per dose were treated nose only by inhalation with 5, 50, and 260 ppm of the test substance. A post exposure period of two weeks was included. Animals were exposed for 6 hours/day 5 days/week for two weeks daily, at a total of 9 exposures. Control animals were included and received no treatment. Satellite groups were included investigating neurotoxicity. Irregular respiration in the high dose group. Other clinical observations occurred sporadically in all groups including controls and were considered incidental. Body weight was significantly reduced at >= 50 ppm, but was reversible. A diminished or absent response to an alerting stimulus was observed in the high dose group. Mean foot splay was significantly decreased on days 4 and 9 in the high dose group. The incidence of defecation was decreased in the 50 and 260 ppm groups during the motor activity assessments. Beyond this, there were no statistically significant or toxicologically remarkable neurobehavioral differences between the control and treatment groups. Effects only occurred in the nasal tissue of the high dose group. Minimal degeneration / necrosis of olfactory epithelium occurred in the anterior portion of the nose of 4/5 rats exposed to 260 ppm. This lesion was observed neither in the 260 ppm recovery group, which suggests reversibility, nor in the lower dosed groups. A NOAEC of 33.4 mg/m³ was concluded (1996, K2).
Although effects on body weight and certain neurobehavioral differences were observed, these effects were not considered to support classification for specific target organ toxicity following repeated exposure according to Regulation (EC) 1272/2008.
Dermal
No study investigating the dermal repeated exposure toxicity potential was available.
Justification for classification or non-classification
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. As a result, the substance is not considered to be classified for repeated oral, inhalation or dermal dose toxicity under Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.